The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Valproic Acid in Pregnancy Revisited: Neurobehavioral, Biochemical and Molecular Changes Affecting the Embryo and Fetus in Humans and in Animals: A Narrative Review
Abstract
Valproic acid (VPA) is a very effective anticonvulsant and mood stabilizer with relatively few side effects. Being an epigenetic modulator, it undergoes clinical trials for the treatment of advanced prostatic and breast cancer. However, in pregnancy, it seems to be the most teratogenic antiepileptic drug. Among the proven effects are congenital malformations in about 10%. The more common congenital malformations are neural tube defects, cardiac anomalies, urogenital malformations including hypospadias, skeletal malformations and orofacial clefts. These effects are dose related; daily doses below 600 mg have a limited teratogenic potential. VPA, when added to other anti-seizure medications, increases the malformations rate. It induces malformations even when taken for indications other than epilepsy, adding to the data that epilepsy is not responsible for the teratogenic effects. VPA increases the rate of neurodevelopmental problems causing reduced cognitive abilities and language impairment. It also increases the prevalence of specific neurodevelopmental syndromes like autism (ASD) and Attention Deficit Hyperactivity Disorder (ADHD). High doses of folic acid administered prior to and during pregnancy might alleviate some of the teratogenic effect of VPA and other AEDs. Several teratogenic mechanisms are proposed for VPA, but the most important mechanisms seem to be its effects on the metabolism of folate, SAMe and histones, thus affecting DNA methylation. VPA crosses the human placenta and was found at higher concentrations in fetal blood. Its concentrations in milk are low, therefore nursing is permitted. Animal studies generally recapitulate human data.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition to behavioral deficits, a reduced number of neurons in motor cranial nerves nuclei, reduced Purkinje cells, and size of the cerebellar hemispheres, as well as changes in the expression of many genes, some of them found to be associated with human ASD, have been reported in VPA-induced ASD-like behavioral models [49] (Table 2).”
From Animal Models of Autistic-like Behavior in Rodents: A Scoping Review and Call for a Comprehensive Scoring System (2024) · cites this paper as [49]
In the citing paper
“VPA models have demonstrated both construct and face validity in similarity to human ASD symptoms [14,49].”
From Animal Models of Autistic-like Behavior in Rodents: A Scoping Review and Call for a Comprehensive Scoring System (2024) · cites this paper as [49]
In the citing paper
“Non-genetic rodent models are widely used models of ASD-like behavior because of their preclinical and clinical relevance, validity in disease etiology, and resemblance to human symptoms [5,49].”
From Animal Models of Autistic-like Behavior in Rodents: A Scoping Review and Call for a Comprehensive Scoring System (2024) · cites this paper as [49]
In the citing paper
“Exposing pregnant rodents to VPA has been established as a modeling tool for studying ASD-like behavior [49,66,67].”
From Animal Models of Autistic-like Behavior in Rodents: A Scoping Review and Call for a Comprehensive Scoring System (2024) · cites this paper as [49]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prenatal Valproate Exposure and Risk of Autism Spectrum Disorders and Childhood Autism
Christensen, J., Grønborg, T. K., Sørensen, M. J., Schendel, D., Parner, E. T., Pedersen, L. H., & Vestergaard, M. (2013) · JAMA · doi:10.1001/jama.2013.2270 · Cited by 1,357
Common circuit defect of excitatory-inhibitory balance in mouse models of autism
Gogolla, N., LeBlanc, J. J., Quast, K. B., Südhof, T. C., Fagiolini, M., & Hensch, T. K. (2009) · Journal of Neurodevelopmental Disorders · doi:10.1007/s11689-009-9023-x · Cited by 610 · cited 1×
“In the parietal and occipital lobes of mouse cerebral cortex, VPA induced a characteristic asymmetry of parvalbumin (PV) cell reduction across hemispheres [129].”
BackgroundA clinical study of 57 children with fetal anticonvulsant syndromes
Moore, S. J., Turnpenny, P., Quinn, A., Glover, S., Lloyd, D. J., Montgomery, T., & Dean, J. C. S. (2000) · Journal of Medical Genetics · doi:10.1136/jmg.37.7.489 · Cited by 562
Valproic acid in pregnancy: how much are we endangering the embryo and fetus?
Ornoy, A. (2009) · Reproductive Toxicology · doi:10.1016/j.reprotox.2009.02.014 · Cited by 526
Self-citationRose, S., Melnyk, S., Pavliv, O., Bai, S., Nick, T. G., Frye, R. E., & James, S. J. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.61 · Cited by 480
Characteristics of fetal anticonvulsant syndrome associated autistic disorder
Rasalam, A., Hailey, H., Williams, J., Moore, S., Turnpenny, P., Lloyd, D., & Dean, J. (2005) · Developmental Medicine & Child Neurology · doi:10.1017/s0012162205001076 · Cited by 456
Samrén, E. B., van Duijn, C. M., Koch, S., Hiilesmaa, V. K., Klepel, H., Bardy, A. H., Mannagetta, G. B., Deichl, A. W., Gaily, E., Granström, I. L., et al. (1997) · Epilepsia · doi:10.1111/j.1528-1157.1997.tb01480.x · Cited by 406 · cited 1×
“In a study that pooled data from five European prospective studies, Samren et al. [59] found that the rate of MCMs among the offspring of epileptic mothers treated only with VPA was 9%, and if VPA was given with other AEDs it raised the rate to 15.3%.”
BackgroundInfluentialManagement of bipolar disorder during pregnancy and the postpartum period
Yonkers, K. A., Wisner, K. L., Stowe, Z., Leibenluft, E., Cohen, L., Miller, L., Manber, R., Viguera, A., Suppes, T., & Altshuler, L. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.4.608 · Cited by 394
Ingram, J. L., Peckham, S. M., Tisdale, B., & Rodier, P. M. (2000) · Neurotoxicology and Teratology · doi:10.1016/s0892-0362(99)00083-5 · Cited by 381
Valproate Induces Replication-independent Active DNA Demethylation
Detich, N., Bovenzi, V., & Szyf, M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303740200 · Cited by 345
Prenatal, perinatal, and neonatal risk factors of autism spectrum disorder
Hisle-Gorman, E., Susi, A., Stokes, T., Gorman, G., Erdie-Lalena, C., & Nylund, C. M. (2018) · Pediatric Research · doi:10.1038/pr.2018.23 · Cited by 163
Child development following in utero exposure: Levetiracetam vs sodium valproate
Shallcross, R., Bromley, R. L., Irwin, B., Bonnett, L. J., Morrow, J., & Baker, G. A. (2011) · Neurology · doi:10.1212/wnl.0b013e3182088297 · Cited by 161 · cited 2×
“Shallcross et al. [78], in the UK, studied the neurodevelopment of 44 VPA-exposed infants of less than 24 months of age in comparison to 51 infants born to mothers treated with levetiracetam and 97 controls using the Griffith Mental Development Scales.”
Christensen, J., Pedersen, L., Sun, Y., Dreier, J. W., Brikell, I., & Dalsgaard, S. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2018.6606 · Cited by 127 · cited 2×
“These changes may affect language development, learning abilities and even cause Autism Spectrum Disorder (ASD) or Attention Deficit Hyperactivity Disorder (ADHD) as well as learning difficulties [24–26].”
BackgroundInfluentialIs autism due to brain desynchronization?
Welsh, J. P., Ahn, E. S., & Placantonakis, D. G. (2005) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2004.09.002 · Cited by 108 · cited 1×
“The suggested mechanisms of action in the brain include increased glutamatergic neural density which leads to an excitatory/inhibitory imbalance, altered monoamines brain turnover, increased reactive oxygen species and epigenetic modifications [118,164].”
BackgroundPhosphoinositides in the regulation of actin cortex and cell migration
Tsujita, K., & Itoh, T. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2014.10.011 · Cited by 66 · cited 1×
“Therefore, depletion in the levels of inositol may have severe adverse developmental consequences [219–222].”
BackgroundMowery, T. M., Wilson, S. M., Kostylev, P. V., Dina, B., Buchholz, J. B., Prieto, A. L., & Garraghty, P. E. (2015) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2014.10.003 · Cited by 29 · cited 1×
“Mowery et al. [124] reported related abnormalities in the cerebellar nuclei of rodents prenatally exposed to VPA, with interpositus, fastigial and dentate nuclei of the cerebellum mostly affected.”
Background
Research works printed but not linked: 230
- Ornoy, 2003, The impact of intrauterine exposure versus postnatal environment in neurodevelopmental toxicity: Long-term neurobehavioral studies in children at risk for developmental disorders, Toxicol. Lett., 140–141, 171, 10.1016/S0378-4274(02)00505-2 · DOI
- Arnon, 2000, The use of psychiatric drugs in pregnancy and lactation, Isr. J. Psychiatry Relat. Sci., 37, 205
- Jentink, 2010, Valproic acid monotherapy in pregnancy and major congenital malformations, New Engl. J. Med., 362, 2185, 10.1056/NEJMoa0907328 · DOI · Paper page
- Ornoy, 2006, Neuroteratogens in man: An overview with special emphasis on the teratogenicity of antiepileptic drugs in pregnancy, Reprod. Toxicol., 22, 214, 10.1016/j.reprotox.2006.03.014 · DOI
- Kultima, 2004, Valproic Acid Teratogenicity: A Toxicogenomics Approach, Environ. Health Perspect., 112, 1225, 10.1289/txg.7034 · DOI
- Shechtman, 2008, Pregnancy outcome after in utero exposure to valproate: Evidence of dose relationship in teratogenic effect, CNS Drugs, 22, 325, 10.2165/00023210-200822040-00004 · DOI
- Morrow, 2006, Malformation risks of antiepileptic drugs in pregnancy: A prospective study from the UK Epilepsy and Pregnancy Register, J. Neurol. Neurosurg. Psychiatry, 77, 193, 10.1136/jnnp.2005.074203 · DOI · Paper page
- Bromley, 2014, Treatment for epilepsy in pregnancy: Neurodevelopmental outcomes in the child, Cochrane Database Syst. Rev., 10, CD010236
- Weston, 2016, Monotherapy treatment of epilepsy in pregnancy: Congenital malformation outcomes in the child, Cochrane Database Syst. Rev., 11, CD010224
- Kini, 2006, Dysmorphic features: An important clue to the diagnosis and severity of fetal anticonvulsant syndromes, Arch. Dis. Child. Fetal Neonatal Ed., 91, F90, 10.1136/adc.2004.067421 · DOI
- Fried, 2004, Malformation rates in children of women with untreated epilepsy: A meta-analysis, Drug Saf., 27, 197, 10.2165/00002018-200427030-00004 · DOI · Paper page
- Anmella, 2019, Expert advice on the management of valproate in women with bipolar disorder at childbearing age, Eur. Neuropsychopharmacol. J. Eur. Coll. Neuropsychopharmacol., 29, 1199, 10.1016/j.euroneuro.2019.09.007 · DOI
- Speidel, 1972, Maternal epilepsy and abnormalities of the fetus and newborn, Lancet, 2, 839, 10.1016/S0140-6736(72)92209-X · DOI · Paper page
- Bjerkedal, 1973, The course and outcome of pregnancy in women with epilepsy, Acta Obs. Gynecol. Scand., 52, 245, 10.3109/00016347309158321 · DOI
- Shapiro, 1976, Anticonvulsants and parental epilepsy in the development of birth defects, Lancet, 1, 272, 10.1016/S0140-6736(76)91403-3 · DOI · Paper page
- DiLiberti, 1984, The fetal valproate syndrome, Am. J. Med. Genet., 19, 473, 10.1002/ajmg.1320190308 · DOI · Paper page
- Kozma, 2001, Valproic acid embryopathy: Report of two siblings with further expansion of the phenotypic abnormalities and a review of the literature, Am. J. Med. Genet., 98, 168, 10.1002/1096-8628(20010115)98:2<168::AID-AJMG1026>3.0.CO;2-O · DOI
- Bulut, 2017, Fetal Valproate Syndrome, Pediatr. Neonatol., 58, 158, 10.1016/j.pedneo.2016.01.009 · DOI
- Bromley, 2019, Diagnosis and management of individuals with Fetal Valproate Spectrum Disorder; a consensus statement from the European Reference Network for Congenital Malformations and Intellectual Disability, Orphanet J. Rare Dis., 14, 180, 10.1186/s13023-019-1064-y · DOI
- Ardinger, 1988, Verification of the fetal valproate syndrome phenotype, Am. J. Med. Genet., 29, 171, 10.1002/ajmg.1320290123 · DOI · Paper page
- Bromley, 2019, Intellectual functioning in clinically confirmed fetal valproate syndrome, Neurotoxicol. Teratol., 71, 16, 10.1016/j.ntt.2018.11.003 · DOI
- Bromley, 2023, Monotherapy treatment of epilepsy in pregnancy: Congenital malformation outcomes in the child, Cochrane Database Syst. Rev., 8, CD010224
- Rihtman, 2013, Developmental outcomes at preschool age after fetal exposure to valproic acid and lamotrigine: Cognitive, motor, sensory and behavioral function, Reprod. Toxicol., 41, 115, 10.1016/j.reprotox.2013.06.001 · DOI
- Cohen, 2019, Fetal antiepileptic drug exposure and learning and memory functioning at 6 years of age: The NEAD prospective observational study, Epilepsy Behav., 92, 154, 10.1016/j.yebeh.2018.12.031 · DOI
- Ornoy, A., Becker, M., Weinstein-Fudim, L., and Ergaz, Z. (2020). S-Adenosine Methionine (SAMe) and Valproic Acid (VPA) as Epigenetic Modulators: Special Emphasis on their Interactions Affecting Nervous Tissue during Pregnancy. Int. J. Mol. Sci., 21. · DOI · Paper page
- Singh, D., Gupta, S., Verma, I., Morsy, M.A., Nair, A.B., and Ahmed, A.F. (2021). Hidden pharmacological activities of valproic acid: A new insight. Biomed. Pharmacother., 142. · DOI
- Verloes, 1990, Proximal phocomelia and radial ray aplasia in fetal valproic syndrome, Eur. J. Pediatr., 149, 266, 10.1007/BF02106290 · DOI
- Bromfield, 2008, Valproate teratogenicity and epilepsy syndrome, Epilepsia, 49, 2122, 10.1111/j.1528-1167.2008.01696.x · DOI
- Tanoshima, 2015, Risks of congenital malformations in offspring exposed to valproic acid in utero: A systematic review and cumulative meta-analysis, Clin. Pharmacol. Ther., 98, 417, 10.1002/cpt.158 · DOI
- Eadie, 2005, Should valproate be taken during pregnancy?, Ther. Clin. Risk Manag., 1, 21, 10.2147/tcrm.1.1.21.53605 · DOI
- Campbell, 2014, Malformation risks of antiepileptic drug monotherapies in pregnancy: Updated results from the UK and Ireland Epilepsy and Pregnancy Registers, J. Neurol. Neurosurg. Psychiatry, 85, 1029, 10.1136/jnnp-2013-306318 · DOI · Paper page
- Artama, 2005, Antiepileptic drug use of women with epilepsy and congenital malformations in offspring, Neurology, 64, 1874, 10.1212/01.WNL.0000163771.96962.1F · DOI · Paper page
- Smith, 2012, Comparative safety of antiepileptic drugs during pregnancy, Neurology, 78, 1692, 10.1212/WNL.0b013e3182574f39 · DOI · Paper page
- Vajda, 2007, The Australian Register of Antiepileptic Drugs in Pregnancy: The first 1002 pregnancies, Aust. N. Z. J. Obstet. Gynaecol., 47, 468, 10.1111/j.1479-828X.2007.00781.x · DOI
- Ornoy, 1993, Clinical teratology, West. J. Med., 159, 382
- Philbrook, 2019, Characterizing the effects of in utero exposure to valproic acid on murine fetal heart development, Birth Defects Res., 111, 1551, 10.1002/bdr2.1610 · DOI
- Yerby, 1994, Pregnancy, teratogenesis, and epilepsy, Neurol. Clin., 12, 749, 10.1016/S0733-8619(18)30075-6 · DOI
- Bjerkedal, 1982, Valproic acid and spina bifida, Lancet, 2, 1096, 10.1016/S0140-6736(82)90018-6 · DOI · Paper page
- Kim, 1994, Developmental abnormalities of the female reproductive tract, Curr. Opin. Obstet. Gynecol., 6, 518, 10.1097/00001703-199412000-00009 · doi:10.1097/00001703-199412000-00009
- Okada, 2004, Amidic modification of valproic acid reduces skeletal teratogenicity in mice, Birth Defects Res. Part B Dev. Reprod. Toxicol., 71, 47, 10.1002/bdrb.10057 · doi:10.1002/bdrb.10057
- Yerby, 2003, Management issues for women with epilepsy: Neural tube defects and folic acid supplementation, Neurology, 61, S23, 10.1212/WNL.61.6_suppl_2.S23 · DOI
- Koren, 2006, Major malformations with valproic acid, Can. Fam. Physician Med. Fam. Can., 52, 441
- Perucca, 2006, Prenatal exposure to antiepileptic drugs, Lancet, 367, 1467, 10.1016/S0140-6736(06)68627-3 · DOI
- Malm, 2002, Valproate embryopathy in three sets of siblings: Further proof of hereditary susceptibility, Neurology, 59, 630, 10.1212/WNL.59.4.630 · DOI
- Alsdorf, 2005, Teratogenicity of sodium valproate, Expert. Opin. Drug Saf., 4, 345, 10.1517/14740338.4.2.345 · DOI · Paper page
- 2008, Risk of hypospadias in newborn infants exposed to valproic acid during the first trimester of pregnancy: A case-control study in Spain, Drug Saf., 31, 537, 10.2165/00002018-200831060-00008 · DOI
- Dalens, 1980, Bronchopulmonary dysplasia following negative pressure ventilation, J. Pediatr., 97, 332, 10.1016/S0022-3476(80)80517-8 · DOI
- Gomez, 1981, Possible teratogenicity of valproic acid, J. Pediatr., 98, 508, 10.1016/S0022-3476(81)80743-3 · DOI
- Lindhout, 1992, Spectrum of neural-tube defects in 34 infants prenatally exposed to antiepileptic drugs, Neurology, 42, 111
- Robert, 1983, Is valproic acid teratogenic?, Rev. Neurol., 139, 445
- Kaneko, 1999, Congenital malformations due to antiepileptic drugs, Epilepsy Res., 33, 145, 10.1016/S0920-1211(98)00084-9 · DOI · Paper page
- Matalon, 2002, The teratogenic effect of carbamazepine: A meta-analysis of 1255 exposures, Reprod. Toxicol., 16, 9, 10.1016/S0890-6238(01)00199-X · DOI · Paper page
- Laegreid, 1993, Benzodiazepine amplification of valproate teratogenic effects in children of mothers with absence epilepsy, Neuropediatrics, 24, 88, 10.1055/s-2008-1071520 · DOI
- Holmes, 2011, Fetal effects of anticonvulsant polytherapies: Different risks from different drug combinations, Arch Neurol., 68, 1275, 10.1001/archneurol.2011.133 · DOI · Paper page
- Tomson, 2015, Valproate in the treatment of epilepsy in girls and women of childbearing potential, Epilepsia, 56, 1006, 10.1111/epi.13021 · DOI · Paper page
- Zaccara, 2014, Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs, Epileptic Disord. Int. Epilepsy J. Videotape, 16, 409, 10.1684/epd.2014.0714 · DOI · Paper page
- Mawer, 2002, Outcome of pregnancy in women attending an outpatient epilepsy clinic: Adverse features associated with higher doses of sodium valproate, Seizure, 11, 512, 10.1016/S1059-1311(02)00135-8 · DOI
- Winter, 1987, Fetal valproate syndrome: Is there a recognisable phenotype?, J. Med. Genet., 24, 692, 10.1136/jmg.24.11.692 · DOI
- Dean, 2000, Developing diagnostic criteria for the fetal anticonvulsant syndromes, Seizure, 9, 233, 10.1053/seiz.2000.0392 · DOI
- Koch, 1996, Antiepileptic drug treatment in pregnancy: Drug side effect in the neonate and neurological outcome, Acta Paediatr. Int. J. Paediatr., 85, 739, 10.1111/j.1651-2227.1996.tb14137.x · DOI
- Nicolai, 2008, Neurodevelopmental delay in children exposed to antiepileptic drugs in utero: A critical review directed at structural study-bias, J. Neurol. Sci., 271, 1, 10.1016/j.jns.2008.03.004 · DOI
- Christianson, 1994, Fetal Valproate Syndrome: Clinical and Neuro-developmental Features in Two Sibling Pairs, Dev. Med. Child Neurol., 36, 361, 10.1111/j.1469-8749.1994.tb11858.x · DOI · Paper page
- Dean, 2002, Long term health and neurodevelopment in children exposed to antiepileptic drugs before birth, J. Med. Genet., 39, 251, 10.1136/jmg.39.4.251 · DOI · Paper page
- Viinikainen, 2006, The effects of valproate exposure in utero on behavior and the need for educational support in school-aged children, Epilepsy Behav., 9, 636, 10.1016/j.yebeh.2006.08.007 · DOI
- Adab, 2001, Additional educational needs in children born to mothers with epilepsy, J. Neurol. Neurosurg. Psychiatry, 70, 15, 10.1136/jnnp.70.1.15 · DOI · Paper page
- Adab, 2004, The longer term outcome of children born to mothers with epilepsy, J. Neurol. Neurosurg. Psychiatry, 75, 1575, 10.1136/jnnp.2003.029132 · DOI · Paper page
- Langer, 1994, Isolated fetal bilateral radial ray reduction associated with valproic acid usage, Fetal Diagn. Ther., 9, 155, 10.1159/000263924 · DOI
- Gaily, 2004, Normal intelligence in children with prenatal exposure to carbamazepine, Neurology, 62, 28, 10.1212/WNL.62.1.28 · DOI · Paper page
- Eriksson, 2005, Children exposed to valproate in utero—population based evaluation of risks and confounding factors for long-term neurocognitive development, Epilepsy Res., 65, 189, 10.1016/j.eplepsyres.2005.06.001 · DOI
- Daugaard, 2020, Association of Prenatal Exposure to Valproate and Other Antiepileptic Drugs with Intellectual Disability and Delayed Childhood Milestones, JAMA Netw. Open, 3, e2025570, 10.1001/jamanetworkopen.2020.25570 · DOI
- Tomson, 2019, Management of epilepsy in pregnancy: A report from the International League Against Epilepsy Task Force on Women and Pregnancy, Epileptic Disord., 21, 497, 10.1684/epd.2019.1105 · DOI · Paper page
- Wiggs, 2020, Antiseizure medication use during pregnancy and risk of ASD and ADHD in children, Neurology, 95, e3232, 10.1212/WNL.0000000000010993 · DOI
- Williams, 1997, A male with fetal valproate syndrome and autism, Dev. Med. Child Neurol., 39, 632, 10.1111/j.1469-8749.1997.tb07500.x · DOI · Paper page
- Bromley, 2013, The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs, J. Neurol. Neurosurg. Psychiatry, 84, 637, 10.1136/jnnp-2012-304270 · DOI · Paper page
- Wood, 2015, Prospective assessment of autism traits in children exposed to antiepileptic drugs during pregnancy, Epilepsia, 56, 1047, 10.1111/epi.13007 · DOI
- Honybun, 2021, Prenatal valproate exposure and adverse neurodevelopmental outcomes: Does sex matter?, Epilepsia, 62, 709, 10.1111/epi.16827 · DOI
- Petersen, 2016, Risks and benefits of psychotropic medication in pregnancy: Cohort studies based on UK electronic primary care health records, Health Technol. Assess., 20, 1, 10.3310/hta20230 · DOI
- Pittschieler, 2008, Spontaneous abortion and the prophylactic effect of folic acid supplementation in epileptic women undergoing antiepileptic therapy, J. Neurol., 255, 1926, 10.1007/s00415-008-0029-1 · DOI
- Błaszczyk, B., Miziak, B., Pluta, R., and Czuczwar, S.J. (2022). Epilepsy in Pregnancy-Management Principles and Focus on Valproate. Int. J. Mol. Sci., 23. · DOI
- Baxter, 2014, Valproate and folic acid in pregnancy: Associations with autism, Dev. Med. Child Neurol., 56, 604, 10.1111/dmcn.12498 · DOI
- Janz, D., Bossi, L., Dam, M., Helge, H., Richens, A., and Schmidt, D. (1982). Epilepsy, Pregnancy, and the Child, Raven Press.
- Albani, 1984, Differential transplacental binding of valproic acid: Influence of free fatty acids, Br. J. Clin. Pharmacol., 17, 759, 10.1111/j.1365-2125.1984.tb02414.x · DOI
- Kacirova, 2015, Serum levels of valproic acid during delivery in mothers and in umbilical cord—Correlation with birth length and weight, Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czechoslov., 159, 569, 10.5507/bp.2015.055 · DOI
- Kacirova, I., Grundmann, M., and Brozmanova, H. (2021). Valproic Acid Concentrations in Mothers, Colostrum and Breastfed Infants during the Early Postpartum Period: Comparison with Concentrations Determined during Delivery and in the Mature Milk Period. Pharmaceutics, 13. · DOI
- Froescher, 1984, Valproic acid in breast milk: How much is really there?, Ther. Drug Monit., 6, 272, 10.1097/00007691-198409000-00003 · DOI
- Bennet, P.N. (1988). Drugs and Human Lactation, Elsevier.
- Swanson, 1978, Excretion of valproic acid into semen of rabbits and man, Epilepsia, 19, 541, 10.1111/j.1528-1157.1978.tb05034.x · DOI
- Yerby, 1999, Male infertility: Possible association with valproate exposure, Epilepsia, 40, 520, 10.1111/j.1528-1157.1999.tb00752.x · DOI
- Kaaja, 2003, Major malformations in offspring of women with epilepsy, Neurology, 60, 575, 10.1212/01.WNL.0000044157.28073.DC · DOI · Paper page
- Janz, 1994, Are antiepileptic drugs harmful when taken during pregnancy?, J. Perinat. Med., 22, 367
- Bold, 2018, Spinal nerve defects in mouse embryos prenatally exposed to valproic acid, Anat. Sci. Int., 93, 35, 10.1007/s12565-016-0363-9 · DOI
- Giavini, 2013, Methionine pretreatment enhances the effects of valproate on axial development in a cd1 mouse model, Birth Defects Res. Part B-Dev. Reprod. Toxicol., 98, 328, 10.1002/bdrb.21069 · DOI
- Shafique, 2021, Gestational valproic acid exposure induces epigenetic modifications in murine decidua, Placenta, 107, 31, 10.1016/j.placenta.2021.03.004 · DOI
- Tiboni, 2015, Prevention of valproic acid-induced neural tube defects by sildenafil citrate, Reprod. Toxicol., 56, 175, 10.1016/j.reprotox.2015.03.004 · DOI
- Elphick, 2012, Conserved valproic-acid-induced lipid droplet formation in Dictyostelium and human hepatocytes identifies structurally active compounds, Dis. Models Mech., 5, 231, 10.1242/dmm.008391 · doi:10.1242/dmm.008391
- Goetzl, L. (2012). Queenan’s Management of High-Risk Pregnancy: An Evidence-Based Approach, Wiley-Blackwell.
- Salimi, 2022, Selenium and L-carnitine protects from valproic acid-Induced oxidative stress and mitochondrial damages in rat cortical neurons, Drug Chem. Toxicol., 45, 1150, 10.1080/01480545.2020.1810259 · DOI
- Shafique, 2020, Role of Cbp, p300 and Akt in valproic acid induced neural tube defects in CD-1 mouse embryos, Reprod. Toxicol., 95, 86, 10.1016/j.reprotox.2020.05.008 · DOI
- Takla, T.N., Luo, J., Sudyk, R., Huang, J., Walker, J.C., Vora, N.L., Sexton, J.Z., Parent, J.M., and Tidball, A.M. (2023). A Shared Pathogenic Mechanism for Valproic Acid and SHROOM3 Knockout in a Brain Organoid Model of Neural Tube Defects. Cells, 12. · doi:10.1101/2023.04.11.536245
- Tiboni, 2021, Valproic acid alters nitric oxide status in neurulating mouse embryos, Reprod. Toxicol., 99, 152, 10.1016/j.reprotox.2020.08.012 · DOI
- Wachholz, 2021, From the Farm to the Lab: How Chicken Embryos Contribute to the Field of Teratology, Front. Genet., 12, 666726, 10.3389/fgene.2021.666726 · DOI
- Binkerd, 1988, Evaluation of valproic acid (VPA) developmental toxicity and pharmacokinetics in Sprague-Dawley rats, Fundam. Appl. Toxicol. Off. J. Soc. Toxicol., 11, 485, 10.1093/toxsci/11.1.485 · doi:10.1093/toxsci/11.1.485
- Lin, 2019, Teratogenicity of valproic acid and its constitutional isomer, amide derivative valnoctamide in mice, Birth Defects Res., 111, 1013, 10.1002/bdr2.1406 · DOI
- Hendrickx, 1988, Valproic acid developmental toxicity and pharmacokinetics in the rhesus monkey: An interspecies comparison, Teratology, 38, 329, 10.1002/tera.1420380405 · DOI
- Jazayeri, 2020, A rat model of valproate teratogenicity from chronic oral treatment during pregnancy, Epilepsia, 61, 1291, 10.1111/epi.16536 · DOI
- Menegola, 1996, Teratogenic effects of sodium valproate in mice and rats at midgestation and at term, Teratog. Carcinog. Mutagen., 16, 97, 10.1002/(SICI)1520-6866(1996)16:2<97::AID-TCM4>3.0.CO;2-A · DOI
- Ornoy, 2019, S-adenosyl methionine prevents ASD like behaviors triggered by early postnatal valproic acid exposure in very young mice, Neurotoxicol. Teratol., 71, 64, 10.1016/j.ntt.2018.01.005 · DOI · Paper page
- Broccia, 2010, VPA-related axial skeletal defects and apoptosis: A proposed event cascade, Reprod. Toxicol., 29, 106, 10.1016/j.reprotox.2009.10.004 · DOI
- Elmazar, 1993, Trimethoprim potentiates valproic acid-induced Neural Tube Defects (NTDs) in mice, Reprod. Toxicol., 7, 249, 10.1016/0890-6238(93)90231-U · DOI
- Banji, 2011, Amelioration of behavioral aberrations and oxidative markers by green tea extract in valproate induced autism in animals, Brain Res., 1410, 141, 10.1016/j.brainres.2011.06.063 · DOI
- Nau, 2011, Potency ranking of valproic acid analogues as to inhibition of cardiac differentiation of embryonic stem cells in comparison to their in vivo embryotoxicity, Reprod. Toxicol., 31, 375, 10.1016/j.reprotox.2010.11.012 · DOI
- Michaelis, 2004, Valproic Acid Inhibits Angiogenesis in Vitro and in Vivo, Mol. Pharmacol., 65, 520, 10.1124/mol.65.3.520 · DOI · Paper page
- Nau, 1991, Valproic Acid-Induced Neural Tube Defects in Mouse and Human: Aspects of Chirality, Alternative Drug Development, Pharmacokinetics and Possible Mechanisms, Pharmacol. Toxicol., 69, 310, 10.1111/j.1600-0773.1991.tb01303.x · DOI · Paper page
- Wang, 2010, Selective neuronal vulnerability to oxidative stress in the brain, Front. Aging Neurosci., 2, 12
- Wegner, 1991, Diurnal variation of folate concentrations in mouse embryo and plasma: The protective effect of folinic acid on valproic-acid-induced teratogenicity is time dependent, Reprod. Toxicol., 5, 465, 10.1016/0890-6238(91)90017-A · DOI
- Hara, 2012, Effect of prenatal valproic acid exposure on cortical morphology in female mice, J. Pharmacol. Sci., 118, 543, 10.1254/jphs.12025SC · DOI
- Sawada, K., Kamiya, S., and Aoki, I. (2021). Neonatal valproic acid exposure produces altered gyrification related to increased parvalbumin-immunopositive neuron density with thickened sulcal floors. PLoS ONE, 16. · DOI
- Fueta, 2018, Prenatal exposure to valproic acid alters the development of excitability in the postnatal rat hippocampus, NeuroToxicology, 65, 1, 10.1016/j.neuro.2018.01.001 · DOI
- Ezhilarasan, 2022, Valproic acid induced liver injury: An insight into molecular toxicological mechanism, Environ. Toxicol. Pharmacol., 95, 103967, 10.1016/j.etap.2022.103967 · DOI
- Shakya, 2016, Hepatotoxicity of Valproate on Fetal Mice Liver, IJSR-Int. J. Sci. Res. Med. Sci., 5, 79
- Akta, 2010, The effects of valproic acid on renal corpuscle of pregnant rats and protective role of folic acid and vitamin E, Afr. J. Biotechnol., 9, 5605
- Raza, 2000, Pathomorphological changes in mouse liver and kidney during prolonged valproate administration, Int. J. Tissue React., 22, 15
- Wu, G., Nan, C., Rollo, J.C., Huang, X., and Tian, J. (2010). Sodium valproate-induced congenital cardiac abnormalities in mice are associated with the inhibition of histone deacetylase. J. Biomed. Sci., 17. · DOI
- Avagliano, 2019, Overview on Neural tube defects: From development to physical characteristics, Birth Defects Res., 111, 1455, 10.1002/bdr2.1380 · DOI · Paper page
- Genton, 2006, Valproic acid in epilepsy: Pregnancy-related issues, Drug Saf., 29, 1, 10.2165/00002018-200629010-00001 · DOI
- Hansen, 2021, Valproic acid promotes SOD2 acetylation: A potential mechanism of valproic acid-induced oxidative stress in developing systems Valproic acid promotes SOD2 acetylation: A potential mechanism of valproic acid-induced oxidative stress in developing systems Valproic acid promotes SOD2 acetylation: A potential mechanism of valproic acid-induced oxidative stress in developing systems, Free Radic. Res., 55, 1130, 10.1080/10715762.2021.2017913 · DOI
- Lundberg, 2004, Mapping a chromosomal locus for valproic acid-induced exencephaly in mice, Mamm. Genome, 15, 361, 10.1007/s00335-004-2345-9 · doi:10.1007/s00335-004-2345-9
- Menegola, 2005, Inhibition of histone deacetylase activity on specific embryonic tissues as a new mechanism for teratogenicity, Birth Defects Res. Part B Dev. Reprod. Toxicol., 74, 392, 10.1002/bdrb.20053 · DOI
- Ehlers, 1996, Methionine Reduces the Valproic Acid-Induced Spina Bifida Rate in Mice without Altering Valproic Acid Kinetics, J. Nutr., 126, 67, 10.1093/jn/126.1.67 · DOI
- Arshaduddin, 2000, Vitamin E decreases valproic acid induced neural tube defects in mice, Neurosci. Lett., 292, 179, 10.1016/S0304-3940(00)01457-9 · DOI
- Chaliha, 2020, A Systematic Review of the Valproic-Acid-Induced Rodent Model of Autism, Dev. Neurosci., 42, 12, 10.1159/000509109 · DOI · Paper page
- Wagner, 2006, A new neurobehavioral model of autism in mice: Pre- and postnatal exposure to sodium valproate, J. Autism Dev. Disord., 36, 779, 10.1007/s10803-006-0117-y · DOI · Paper page
- Arndt, 2005, The teratology of autism, Int. J. Dev. Neurosci., 23, 189, 10.1016/j.ijdevneu.2004.11.001 · DOI · Paper page
- Fereshetyan, 2021, Assessment of behavioral, morphological and electrophysiological changes in prenatal and postnatal valproate induced rat models of autism spectrum disorder, Sci. Rep., 11, 23471, 10.1038/s41598-021-02994-6 · DOI
- Schneider, 2008, Gender-specific behavioral and immunological alterations in an animal model of autism induced by prenatal exposure to valproic acid, Psychoneuroendocrinology, 33, 728, 10.1016/j.psyneuen.2008.02.011 · DOI · Paper page
- Nway, 2018, Social behavior, neuroimmune markers and glutamic acid decarboxylase levels in a rat model of valproic acid-induced autism, J. Toxicol. Sci., 43, 631, 10.2131/jts.43.631 · DOI
- Kawada, 2018, Involvement of endoplasmic reticulum stress and neurite outgrowth in the model mice of autism spectrum disorder, Neurochem. Int., 119, 115, 10.1016/j.neuint.2017.07.004 · DOI
- Diniz, 2021, BALB/c female subjected to valproic acid during gestational period exhibited greater microglial and behavioral changes than male mice: A significant contra intuitive result, Int. J. Dev. Neurosci., 81, 37, 10.1002/jdn.10072 · DOI
- Legato, M.J., Feldberg, D., and Glezerman, M. (2023). Sex, Gender, and Epigenetics: From Molecule to Bedside, Academic Press.
- Ornoy, A., Gorobets, D., Weinstein-Fudim, L., and Becker, M. (2023). Sex-Related Changes in the Clinical, Genetic, Electrophysiological, Connectivity, and Molecular Presentations of ASD: A Comparison between Human and Animal Models of ASD with Reference to Our Data. Int. J. Mol. Sci., 24. · DOI · Paper page
- American Psychiatric Association (2013). Diagnostic and Statistical Manual of Mental Disorders: DSM-5, American Psychiatric Association. · DOI · Paper page
- Rodier, 1996, Embryological origin for autism: Developmental anomalies of the cranial nerve motor nuclei, J. Comp. Neurol., 370, 247, 10.1002/(SICI)1096-9861(19960624)370:2<247::AID-CNE8>3.0.CO;2-2 · doi:10.1002/(sici)1096-9861(19960624)370:2<247::aid-cne8>3.0.co;2-2
- Bailey, 1996, Autism: Towards an Integration of Clinical, Genetic, Neuropsychological, and Neurobiological Perspectives, J. Child Psychol. Psychiatry, 37, 89, 10.1111/j.1469-7610.1996.tb01381.x · DOI · Paper page
- Kobayashi, 2019, Effects of rapamycin on social interaction deficits and gene expression in mice exposed to valproic acid in utero, Mol. Brain, 12, 3, 10.1186/s13041-018-0423-2 · DOI
- Zhao, 2019, Maternal valproic acid exposure leads to neurogenesis defects and autism-like behaviors in non-human primates, Transl. Psychiatry, 9, 267, 10.1038/s41398-019-0608-1 · DOI
- Weinstein-Fudim, L., Ergaz, Z., Turgeman, G., Yanai, J., Szyf, M., and Ornoy, A. (2019). Gender Related Changes in Gene Expression Induced by Valproic Acid in A Mouse Model of Autism and the Correction by S-adenosyl Methionine. Does It Explain the Gender Differences in Autistic Like Behavior?. Int. J. Mol. Sci., 20. · DOI · Paper page
- Ornoy, A., Weinstein-Fudim, L., and Becker, M. (2022). SAMe, Choline, and Valproic Acid as Possible Epigenetic Drugs: Their Effects in Pregnancy with a Special Emphasis on Animal Studies. Pharmaceuticals, 15. · DOI · Paper page
- Wang, 2013, Resting state EEG abnormalities in autism spectrum disorders, J. Neurodev. Disord., 5, 24, 10.1186/1866-1955-5-24 · DOI · Paper page
- Lenart, 2020, Altered expression of glutamatergic and GABAergic genes in the valproic acid-induced rat model of autism: A screening test, Toxicology, 440, 152500, 10.1016/j.tox.2020.152500 · DOI
- Feleke, 2022, Integrative genomics reveals pathogenic mediator of valproate-induced neurodevelopmental disability, Brain, 145, 3832, 10.1093/brain/awac296 · DOI
- Zhang, 2018, Transcriptional and splicing dysregulation in the prefrontal cortex in valproic acid rat model of autism, Reprod. Toxicol., 77, 53, 10.1016/j.reprotox.2018.01.008 · DOI
- Huang, 2016, Functional Genomic Analyses Identify Pathways Dysregulated in Animal Model of Autism, CNS Neurosci. Ther., 22, 845, 10.1111/cns.12582 · DOI
- Guerra, 2023, Fetal exposure to valproic acid dysregulates the expression of autism-linked genes in the developing cerebellum, Transl. Psychiatry, 13, 114, 10.1038/s41398-023-02391-9 · DOI
- Leto, 2016, Consensus Paper: Cerebellar Development, Cerebellum, 15, 789, 10.1007/s12311-015-0724-2 · DOI · Paper page
- Gottshall, 2016, Differential timing of granule cell production during cerebellum development underlies generation of the foliation pattern, Neural Dev., 11, 17, 10.1186/s13064-016-0072-z · DOI
- Sillitoe, 2007, Morphology, molecular codes, and circuitry produce the three-dimensional complexity of the cerebellum, Annu. Rev. Cell Dev. Biol., 23, 549, 10.1146/annurev.cellbio.23.090506.123237 · DOI · Paper page
- Weinstein-Fudim, L., Ergaz, Z., Szyf, M., and Ornoy, A. (2020). Prenatal S-Adenosine Methionine (SAMe) Induces Changes in Gene Expression in the Brain of Newborn Mice That Are Prevented by Co-Administration of Valproic Acid (VPA). Int. J. Mol. Sci., 21. · DOI
- Wegner, 1992, Alteration of embryonic folate metabolism by valproic acid during organogenesis: Implications for mechanism of teratogenesis, Neurology, 42, 17
- Reynolds, 2020, Antiepileptic drugs and folate revisited, Epilepsy Behav., 112, 107336, 10.1016/j.yebeh.2020.107336 · DOI
- Afman, 2006, Genetic variation in genes of folate metabolism and neural-tube defect risk, Proc. Nutr. Soc., 65, 204, 10.1079/PNS2006495 · DOI
- Hansen, 1995, Effect of supplemental folic acid on valproic acid-induced embryotoxicity and tissue zinc levels in vivo, Teratology, 52, 277, 10.1002/tera.1420520506 · DOI
- Semmler, 2017, Intrauterine valproate exposure is associated with alterations in hippocampal cell numbers and folate metabolism in a rat model of valproate teratogenicity, Seizure, 46, 7, 10.1016/j.seizure.2017.01.003 · DOI
- Semmler, 2012, The ratio of S-adenosylmethione and S-adenosyl-homocysteine is increased in the brains of newborn rats in a model of valproic acid teratogenicity, Toxicology, 293, 132, 10.1016/j.tox.2012.01.001 · doi:10.1016/j.tox.2012.01.001
- Bokor, S., Vass, R.A., Funke, S., Ertl, T., and Molnár, D. (2022). Epigenetic Effect of Maternal Methyl-Group Donor Intake on Offspring’s Health and Disease. Life, 12. · DOI
- Clare, 2019, One-Carbon Metabolism: Linking Nutritional Biochemistry to Epigenetic Programming of Long-Term Development, Annu. Rev. Anim. Biosci., 7, 263, 10.1146/annurev-animal-020518-115206 · DOI · Paper page
- Jacob, 2017, VPA Inhibits P19 Neural Differentiation through Redox Dysregulation and Oxidative Stress, Free Radic. Biol. Med., 112, 190, 10.1016/j.freeradbiomed.2017.10.298 · doi:10.1016/j.freeradbiomed.2017.10.298
- Lucas, S., and Hansen, J. (2018). Valproic acid inhibits superoxide dismutase activity in mouse P19 cells. Free Radic. Biol. Med., 128. · doi:10.1016/j.freeradbiomed.2018.10.289
- Piorczynski, 2018, The protective effects of Nrf2 against valproic acid in differentiating P19 cells, Free Radic. Biol. Med., 128, S118, 10.1016/j.freeradbiomed.2018.10.290 · doi:10.1016/j.freeradbiomed.2018.10.290
- Piorczynski, 2022, NRF2 activation protects against valproic acid-induced disruption of neurogenesis in P19 cells, Differentiation, 123, 18, 10.1016/j.diff.2021.12.002 · DOI
- Furugen, 2021, Effects of valproate, an HDAC inhibitor, on the expression of folate carriers and folate metabolism-related genes in the placenta of rats, Drug Metab. Pharmacokinet., 40, 100409, 10.1016/j.dmpk.2021.100409 · DOI
- Reynolds, 2020, Valproate and folate: Congenital and developmental risks, Epilepsy Behav., 108, 107068, 10.1016/j.yebeh.2020.107068 · DOI
- Copp, 2013, Neural tube defects: Recent advances, unsolved questions, and controversies, Lancet Neurol., 12, 799, 10.1016/S1474-4422(13)70110-8 · DOI · Paper page
- Heseker, 2008, Not all cases of neural-tube defect can be prevented by increasing the intake of folic acid, Br. J. Nutr., 102, 173, 10.1017/S0007114508149200 · DOI
- Lawrence, 2009, Examination of selected national policies towards mandatory folic acid fortification, Nutr. Rev., 67, S73, 10.1111/j.1753-4887.2009.00164.x · DOI
- Petersen, 2023, Periconceptional intakes of methyl donors and other micronutrients involved in one-carbon metabolism may further reduce the risk of neural tube defects in offspring: A United States population-based case-control study of women meeting the folic acid recommendations, Am. J. Clin. Nutr., 118, 720, 10.1016/j.ajcnut.2023.05.034 · DOI
- Shaw, 2004, Periconceptional dietary intake of choline and betaine and neural tube defects in offspring, Am. J. Epidemiol., 160, 102, 10.1093/aje/kwh187 · DOI · Paper page
- Williams, 2002, Prevalence of spina bifida and anencephaly during the transition to mandatory folic acid fortification in the United States, Teratology, 66, 33, 10.1002/tera.10060 · DOI · Paper page
- Lin, 2014, S-adenosylmethionine limitation induces p38 mitogen-activated protein kinase and triggers cell cycle arrest in G1, J. Cell Sci., 127, 50
- Akimova, 2017, Metabolite profiling of whole murine embryos reveals metabolic perturbations associated with maternal valproate-induced neural tube closure defects, Birth Defects Res., 109, 106, 10.1002/bdra.23583 · DOI
- D’Souza, S.W., and Glazier, J.D. (2022). Homocysteine Metabolism in Pregnancy and Developmental Impacts. Front. Cell Dev. Biol., 10. · DOI
- Zhu, 2021, Genetic Polymorphisms in Enzymes Involved in One-Carbon Metabolism and Anti-epileptic Drug Monotherapy on Homocysteine Metabolism in Patients with Epilepsy, Front. Neurol., 12, 683275, 10.3389/fneur.2021.683275 · DOI
- Zhao, 2006, Neural tube defects and maternal biomarkers of folate, homocysteine, and glutathione metabolism, Birth Defects Res. Part A Clin. Mol. Teratol., 76, 230, 10.1002/bdra.20240 · DOI
- 2002, Acute Valproate Administration Impairs Methionine Metabolism in Rats, J. Nutr., 132, 2737, 10.1093/jn/132.9.2737 · doi:10.1093/jn/132.9.2737
- Zhang, 2014, Histone deacetylase inhibitors and cell death, Cell. Mol. Life Sci., 71, 3885, 10.1007/s00018-014-1656-6 · DOI · Paper page
- Hsieh, 2013, Valproic acid substantially downregulated genes folr1, IGF2R, RGS2, COL6A3, EDNRB, KLF6, and pax-3, N-acetylcysteine alleviated most of the induced gene alterations in chicken embryo model, Rom. J. Morphol. Embryol., 54, 993
- Hsieh, 2012, Multiple point action mechanism of valproic acid-teratogenicity alleviated by folic acid, vitamin C, and N-acetylcysteine in chicken embryo model, Toxicology, 291, 32, 10.1016/j.tox.2011.10.015 · DOI
- Minucci, 2001, Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells, EMBO J., 20, 6969, 10.1093/emboj/20.24.6969 · DOI · Paper page
- Leung, 2023, Dysregulation of the chromatin environment leads to differential alternative splicing as a mechanism of disease in a human model of autism spectrum disorder, Hum. Mol. Genet., 32, 1634, 10.1093/hmg/ddad002 · DOI
- Danielsson, 2007, Embryonic cardiac arrhythmia and generation of reactive oxygen species: Common teratogenic mechanism for IKr blocking drugs, Reprod. Toxicol., 24, 42, 10.1016/j.reprotox.2007.04.005 · DOI
- Echefu, B.E., Bello, A., Musa, S.A., and Umana, U.E. (2022). Selenium Mitigates Prenatal Lead-Induced Toxicity on Cerebral Cortex of Wistar Rats Pups. Res. Sq., preprint. · doi:10.21203/rs.3.rs-1933946/v1
- Echefu, 2019, Selenium impact assessment on brains of prenatally lead exposed Wistar rats, IBRO Rep., 6, S338, 10.1016/j.ibror.2019.07.1043 · DOI
- Verrotti, 2008, Increased oxidative stress in epileptic children treated with valproic acid, Epilepsy Res., 78, 171, 10.1016/j.eplepsyres.2007.11.005 · DOI
- Ornoy, 2007, Embryonic oxidative stress as a mechanism of teratogenesis with special emphasis on diabetic embryopathy, Reprod. Toxicol., 24, 31, 10.1016/j.reprotox.2007.04.004 · DOI · Paper page
- Rahman, 2015, Astaxanthin improves behavioral disorder and oxidative stress in prenatal valproic acid-induced mice model of autism, Behav. Brain Res., 286, 112, 10.1016/j.bbr.2015.02.041 · DOI
- Finsterer, 2017, Toxicity of antiepileptic drugs to mitochondria, Handb. Exp. Pharmacol., 240, 473, 10.1007/164_2016_2 · doi:10.1007/164_2016_2
- Komulainen, 2015, Sodium valproate induces mitochondrial respiration dysfunction in HepG2 in vitro cell model, Toxicology, 331, 47, 10.1016/j.tox.2015.03.001 · DOI
- Karmirian, 2018, Deformation of Mitochondrial Cristae in Human Neural Progenitor Cells Exposed to Valproic Acid, Acad. Bras. Cienc., 90, 2223, 10.1590/0001-3765201820170762 · DOI
- Sendrowski, 2013, Ultrastructural study of hippocampal cortex neurons in an experimental model of valproate encephalopathy, Folia Histochem. Cytobiol., 51, 31, 10.5603/FHC.2013.005 · DOI
- Hroudova, 2010, Activities of respiratory chain complexes and citrate synthase influenced by pharmacologically different antidepressants and mood stabilizers, Neuro Endocrinol. Lett., 31, 336
- Kudin, A.P., Mawasi, H., Eisenkraft, A., Elger, C.E., Bialer, M., and Kunz, W.S. (2017). Mitochondrial Liver Toxicity of Valproic Acid and Its Acid Derivatives Is Related to Inhibition of α-Lipoamide Dehydrogenase. Int. J. Mol. Sci., 18. · DOI
200 of 230 shown
Cited by
Ornoy, A., Echefu, B., & Becker, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910469 · Cited by 41
Self-citation
Metadata
- Authors
- Ornoy, A., Echefu, B., & Becker, M.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2023-12-27
- Volume
- 25
- Issue
- 1
- Pages
- 390
- ISSN
- 1422-0067
- Cited by
- 69
- References
- 16
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.